Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

An exclusive interview with Pfizer’s Wayne Simmons on reshaping customer experience by listening to those interacting with ...

Pfizer is trading like it caught a cold, despite showing strong financial health post-COVID. In Q4 2024, Pfizer raked in ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

Pfizer Inc. stands out as an undervalued biotech stock with strong dividend potential and ambitious oncology expansion. The company boasts a forward P/E of 8.82, making it significantly cheaper than ...